Followers | 368 |
Posts | 5333 |
Boards Moderated | 1 |
Alias Born | 05/09/2013 |
Wednesday, April 09, 2014 11:05:53 PM
Recent EXEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2024 12:44:31 AM
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November • Business Wire • 11/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/06/2024 12:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/06/2024 12:04:50 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/05/2024 09:23:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2024 10:44:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2024 10:43:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2024 08:54:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2024 08:47:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/30/2024 10:04:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/30/2024 08:10:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2024 08:11:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 08:07:44 PM
- Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update • Business Wire • 10/29/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 08:15:32 PM
- Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 • Business Wire • 10/15/2024 08:05:00 PM
- Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories • Business Wire • 10/15/2024 05:57:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 12:00:17 PM
- Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma • Business Wire • 10/14/2024 12:00:00 PM
- ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS • PR Newswire (Canada) • 10/09/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 01:22:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 01:22:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/23/2024 08:24:20 PM
- Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine • Business Wire • 09/16/2024 12:45:00 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM